Sorted news

ELIXA trial shows CV safety of Lixisenatide

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the ...

12 hours ago
popularity7 comments 0

Study quells concerns about NSAID safety

In older patients with arthritis and no history of cardiovascular disease, chronic use of any non-steroidal anti-inflammatory drug appears safe from a cardiovascular and gastrointestinal stand-point, and regular, non-selective ...

12 hours ago
popularity7 comments 0

Medicare to list 30-minute breast cancer treatment

An innovative radiotherapy technique that has the potential to revolutionise the treatment of early breast cancer will become available and affordable for all eligible women under Medicare from tomorrow.

13 hours ago
popularity25 comments 0